Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira and US Sourced Humira) in Healthy Subjects

Trial Profile

A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira and US Sourced Humira) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Samsung Bioepis
  • Most Recent Events

    • 24 Aug 2017 According to Biogen media release, based on the data from preclinical and clinical data from this and other phase III study (NCT02167139), the European Commission (EC) granted a marketing authorization for IMRALDI for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn's disease, pediatric Crohn's disease, ulcerative colitis and uveitis.
    • 23 Jun 2017 According to Biogen media release, based on the data from preclinical and clinical data from this and other phase III study (NCT02167139), the CHMP of the European Medicines Agency (EMA) has issued a positive opinion for IMRALDI. The positive opinion will now be referred to the European Commission (EC) for marketing authorization in the European Union.
    • 17 Jul 2016 According to Biogen media release, the Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira, has been accepted for review by the European Medicines Agency (EMA) based upon the data from preclinical and clinical data from this and other phase III study (NCT02167139).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top